Any current/future capex/capital investment/strategic investment?

Fineotex Chemical is adding more capacities at its Midland (U.S.) facility with increased R&D team members and machinery investments to support growth. Post-acquisition of CrudeChem (CCT), Fineotex has already invested around $7 million in capex and extended additional funds (~$7 million) for further investments. The company plans to double capacity at CCT, aiming to scale business towards $200 million revenue by 2028, accelerated from earlier 2030 target. There are ongoing discussions and plans for expansion, including inorganic growth opportunities, especially in the U.S. and Middle East mar

Future growth expectations in earnings/operating earnings/profits/EPS?

Fineotex expects significant top-line growth, potentially 3-5x in 3-4 years, driven by strong demand from large global customers like Shell and Exxon. Q4 FY26 sets a base with INR314 crore revenue, with international revenues rising to 70%. EBITDA margin guidance: targeting 18%-20% blended EBITDA, achievable by FY27 or sooner. Oil Specialty Chemicals now contribute ~55-60% of revenue—expected to grow faster than textiles. CrudeChem (CCT) business expected to scale from ~$100 million annualized (Q4 run rate) to $200 million by 2028, with EBITDA margins near 15%. EPS growth aligns with

Current/ Expected Orderbook/ Pending Orders?

The Q4 of FY2025-26 is considered the baseline for future growth at CCT (CrudeChem). The current order book at CCT is described as "too strong" and robust, indicating healthy pending orders. Increasing market demand and strengthened customer trust are driving a growing order pipeline. North American market expansion and new opportunities in the Middle East (e.g., Oman) suggest a rising order book. With capacity enhancements and technology transfers, CCT expects to sustain and grow its order book significantly in the coming years.

IN US

Sale is live|00:00:00left today

Fineotex Chemical LtdQ1 FY26Chemicals & Petrochemicals

Fineotex Chemical Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹43P/E: 27.6Market Cap: ₹2.7K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 1

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

4 of 4 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 1

- Fineotex targets a top-line growth of 3 to 4 times in the next 3-4 years, potentially reaching INR 3,000 crores (Page 16). - Q4 numbers are considered a base, with confidence in continued demand growth from existing customers; oilfield specialty chemicals contribute 55-60% of revenue (Page 19-20). - CCT (US acquisition) is expected to scale revenue from approx. $90-100 million (Q4 annualized) to $200 million by 2028, accelerating from prior 2030 target (Page 6, 7). - Textiles business will continue organic growth but decrease in revenue percentage due to faster oilfield segment growth (Page 19-20). - Expansions like doubling capacity in Midland and increased R&D investment support growth (Page 18-20). - EBITDA margins targeted to improve to 18-20%, indicating operational leverage alongside revenue growth (Page 14, 10). Overall, Fineotex foresees robust growth driven by oilfield specialty chemicals and strategic acquisitions.

Margin guidance

Category 1

→Fineotex expects significant top-line growth, potentially 3-5x in 3-4 years, driven by strong demand from large global customers like Shell and Exxon.
→Q4 FY26 sets a base with INR314 crore revenue, with international revenues rising to 70%.
→EBITDA margin guidance: targeting 18%-20% blended EBITDA, achievable by FY27 or sooner.
→Oil Specialty Chemicals now contribute ~55-60% of revenue—expected to grow faster than textiles.
→CrudeChem (CCT) business expected to scale from ~$100 million annualized (Q4 run rate) to $200 million by 2028, with EBITDA margins near 15%.
→EPS growth aligns with revenue and margin expansion; PAT for FY27 estimated in the range of INR175-185 crore.
→Working capital cycle stable (~79 days), supporting healthy cash flows post-acquisition.
→Strong focus on operational efficiencies and expanding specialty chemical portfolio for sustained profit growth.

3 more insights locked — sign up free to unlock

Fundraise plans

- Fineotex Chemical Limited currently has no debt on its books and is described as a cash-rich company. - Recent acquisitions and capex investments (e.g., $7 million post-acquisition capex for CCT) have been funded internally. - There is no explicit mention of any upcoming or planned fundraising through debt or equity in the call transcript. - The company emphasizes disciplined cash deployment and prefers organic growth and selective inorganic acquisitions funded from internal accruals and cash reserves. - The management highlights a strong financial position enabling focus on growth opportunities without referencing any new equity or debt raising plans. - Any future developments about fundraising, if needed, would likely be communicated transparently to investors via stock exchange disclosures. In summary, Fineotex plans to fund growth from existing cash and internal resources, with no current indication of new debt or equity fundraising.

Order book

Yes

→The Q4 of FY2025-26 is considered the baseline for future growth at CCT (CrudeChem).
→The current order book at CCT is described as "too strong" and robust, indicating healthy pending orders.
→Increasing market demand and strengthened customer trust are driving a growing order pipeline.
→North American market expansion and new opportunities in the Middle East (e.g., Oman) suggest a rising order book.
→With capacity enhancements and technology transfers, CCT expects to sustain and grow its order book significantly in the coming years.

Capex plans

Yes

→Fineotex Chemical is adding more capacities at its Midland (U.S.) facility with increased R&D team members and machinery investments to support growth.
→Post-acquisition of CrudeChem (CCT), Fineotex has already invested around $7 million in capex and extended additional funds (~$7 million) for further investments.
→The company plans to double capacity at CCT, aiming to scale business towards $200 million revenue by 2028, accelerated from earlier 2030 target.
→There are ongoing discussions and plans for expansion, including inorganic growth opportunities, especially in the U.S. and Middle East markets.
→Fineotex has a subsidiary in UAE (Ras Al Khaimah) with plans to start a plant there, and remains open to acquisitions or tie-ups in the region.
→The company remains cash-rich with no debt, enabling disciplined deployment of cash for strategic and organic growth investments.

How does Fineotex Chemical Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Fineotex Chemical Ltd

Rev 1Mar 1

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Fineotex Chemical Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio